Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Flattish volume growth and subdued new launches were key factors for last month
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Acute therapies continue to report strong growth compared to chronic ones.
The company does not expect the outcome of this inspection to impact its plans
Subscribe To Our Newsletter & Stay Updated
